BriaCell Therapeutics Corp. BCTX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -57.67%
- 1 year
- -69.90%
- Market cap
- 26.28M
- EPS (ttm)
- -6.97
- Shares out
- 44.20M
- Forward P/E
- -1.38
- YTD return
- -57.67%
- 1-year return
- -69.90%
- Volume
- 52.81K
- Avg volume
- 265.37K
- Open
- 3.12
- Previous close
- 3.09
- Day's range
- 2.99 – 3.18
- 52-week range
- 2.60 – 13.09
- Beta
- 1.82
- Analysts
- Strong Buy
- Price target
- 15.00 (+398.3%)
- Earnings date
- Oct 28, 2024
2Y -4.69 (-60.91%)
Key statistics
- Enterprise value
- 9.95M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.83M
- Total cash
- 862.09K
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 2.13%
- 50-day average
- 0.7918
- 200-day average
- 1.27
Analyst view
Consensus: strong buy
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 28, 2024
Expected Oct 28, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | -0.08 | -0.22 | -0.14 | -175.00% |
| Oct 28, 2024 | Jul 1, 2024 | -0.52 | — | — | — |
| Oct 28, 2024 | Jul 1, 2024 | -0.52 | -0.07 | +0.45 | +86.54% |
| Jun 14, 2024 | Apr 1, 2024 | -0.55 | — | — | — |
| Jun 14, 2024 | Apr 1, 2024 | -0.55 | 0.11 | +0.66 | +120.00% |
| Mar 18, 2024 | Jan 1, 2024 | -0.20 | -0.71 | -0.51 | -255.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- briacell.com
News
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting 
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study 
Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer 
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center 
BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone 
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ 
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
Your note
Sign in to keep a note on BCTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Lustig (Marc) | 10% Security Holder of Issuer | Acquisition or disposition in the public market | Feb 16, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynwood Capital Management Inc. | 3.61% | 1,597,750 | 857.83K | Mar 30, 2024 |
| Vontobel Holding Limited | 0.18% | 80,000 | 42.95K | Sep 29, 2024 |
| HRT Financial LP | 0.17% | 74,286 | 39.88K | Sep 29, 2024 |
| Onyx Bridge Wealth Group, LLC | 0.11% | 50,000 | 26.84K | Sep 29, 2024 |
| Group One Trading, L.P. | 0.09% | 37,885 | 20.34K | Sep 29, 2024 |
| Summit Trail Advisors, LLC | 0.08% | 35,000 | 18.79K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 7,229 | 3.88K | Oct 30, 2024 |